Skip to main content

Year: 2024

Atlantica Reports Third Quarter 2024 Financial Results

Atlantica Reports Third Quarter 2024 Financial ResultsRevenue for the first nine months of 2024 reached $918.7 million, a 7.0% increase year-over-year compared with $858.6 million in the first nine months of 2023. Adjusted EBITDA was $657.5 million, a 4.8% increase compared with $627.3 million in the first nine months of 2023. Net profit for the first nine months of 2024 attributable to the Company was $32.7 million, compared with a net profit of $46.1 million in the first nine months of 2023. Acquisition by Energy Capital Partners and co-investors remains on track to close December 12, 2024. Quarterly dividend of $0.2225 per share approved by the Board of Directors.November 14, 2024 – Atlantica Sustainable Infrastructure plc (NASDAQ: AY) (“Atlantica” or the “Company”) today reported its financial results for the first nine months...

Continue reading

Natural Gas Services Group, Inc. Reports Third Quarter 2024 Financial and Operating Results; Increases FY 2024 Adjusted EBITDA Guidance

Midland, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) — Natural Gas Services Group, Inc. (“NGS” or the “Company”) (NYSE:NGS), a leading provider of natural gas compression equipment, technology, and services to the energy industry, today announced financial results for the three months ended September 30, 2024. The Company also updated its prior guidance for the full year, increasing its outlook for Adjusted EBITDA, along with providing a preliminary view of expected level of FY 2025 growth capital expenditures. Third Quarter 2024 HighlightsRental revenue of $37.4 million, an increase of 35% when compared to the third quarter of 2023 and 7% sequentially. Net income of $5.0 million, or $0.40 per basic share, as compared to $2.2 million, or $0.18 per basic share in the comparable year-ago period and $4.2 million, or $0.34 per basic share...

Continue reading

OMNIQ Reports $18.5 Million Revenue in the Third Quarter 2024

Focus on Profitability Continues: Reduction in Expenses Drive Higher Margins and Shrinking of LossesOMNIQ Q3 2024 FIGURESOMNIQ Q3 2024 SUMMARYSALT LAKE CITY, Nov. 14, 2024 (GLOBE NEWSWIRE) — omniQ Corporation (OTCMKTS: OMQS) (“omniQ” or “the Company”), reports third quarter 2024 revenue of $18.5 million, signifying 7.57% YoY growth, as well as significant decreases in operational expenses and net loss. FINANCIAL HIGHLIGHTS:Revenue: OMNIQ reported revenue of $18,549,000 for Q3 2024, a modest increase from $17,244,000 in Q3 2023, marking a 7.57% year-over-year growth. Operating Expenses: Decreased significantly to $4,934,000 in Q3 2024 from $6,631,000 in Q3 2023, showing effective cost management resulting in a 25.58% reduction. Net Loss: The Company reported a net loss of $1,599,000 in Q3 2024,...

Continue reading

Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio

– Secures $3.2m in PIPE Financing –– $50m Term Sheet Obtained for Available Financing under Equity Line of Credit – BOSTON and LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX) announces the completion of the merger (the Merger) of Akari Therapeutics, Plc (the Company) and Peak Bio, Inc. (Peak Bio), creating an innovative biotechnology company with a broader focus in the advancement of multiple disease therapies. The combined entity will continue the two companies’ significant progress in the development of Antibody Drug Conjugates (ADCs) and advanced therapies for autoimmune and inflammatory diseases, including Geographic Atrophy (GA). “We have worked throughout this year to bring these two exciting companies together and are thrilled that we have finally completed the merger,”...

Continue reading

ESCO Reports Fourth Quarter and Fiscal 2024 Results

– Q4 Sales increase 9.5% to $299 Million – Q4 GAAP EPS increase 6.5% to $1.32 – Q4 Adjusted EPS increase 16.8% to $1.46 – FY 2024 Sales increase 7.4% to $1.0 Billion – FY 2024 Entered Orders increase 9.7% to $1.1 Billion – FY 2024 GAAP EPS increase 10.1% to $3.94 – FY 2024 Adjusted EPS increase 13.0% to $4.18 – St. Louis, Nov. 14, 2024 (GLOBE NEWSWIRE) — ESCO Technologies Inc. (NYSE: ESE) (ESCO, or the Company) today reported its operating results for the fourth quarter and fiscal year ended September 30, 2024 (Q4 2024 and FY 2024, respectively). Operating HighlightsQ4 2024 Sales increased $26 million (9.5 percent) to $299 million compared to $273 million in Q4 2023. Q4 organic sales increased $23 million (8.5 percent) and the MPE acquisition contributed $3 million (1.0 percent)...

Continue reading

Firsthand Technology Value Fund Announces Third Quarter Financial Results, NAV of $0.22 Per Share

SAN JOSE, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) — Firsthand Technology Value Fund, Inc. (OTCQB: SVVC) (the “Fund”), a publicly traded venture capital fund that invests in technology and cleantech companies, announced today its financial results for the quarter ended September 30, 2024. As of September 30, 2024, the Fund’s net assets were approximately $1.5 million, or $0.22 per share, compared with net assets of approximately $1.0 million, or $0.15 per share as of June 30, 2024. As of September 30, 2024, the Fund’s portfolio included public and private securities valued at approximately $1.4 million, or $0.21 per share, which includes approximately $0.15 per share in cash and cash equivalents. Portfolio Summary (as of 9/30/24)  Investment Fair Value1, Fair Value per Share1,2    Equity/Debt Investments $0.43 million $0.06    Cash/Cash...

Continue reading

Dragonfly Energy Reports Third Quarter 2024 Financial and Operational Results

RENO, Nev., Nov. 14, 2024 (GLOBE NEWSWIRE) — Dragonfly Energy Holdings Corp. (“Dragonfly Energy” or the “Company”) (Nasdaq: DFLI), maker of Battle Born Batteries® and an industry leader in energy storage, today reported its financial and operational results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial HighlightsNet Sales were $12.7 million, compared to $15.9 million in Q3 2023 Gross Profit was $2.9 million, compared to $4.6 million in Q3 2023 Operating Expenses were $(8.9) million, compared to $(10.5) million in Q3 2023 Net Loss of $(6.8) million, compared to Net Loss of $(10.0) million in Q3 2023 Diluted Net Loss per share was $(0.11), compared to Net Loss of $(0.17) per share in Q3 2023 EBITDA was $(0.8) million, compared to $(5.7) million in Q3 2023 Adjusted EBITDA was $(5.5) million, compared...

Continue reading

Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Obtained agreement from FDA to initiate a Phase 1 trial evaluating multiple doses of Rhenium (186Re) Obisbemeda for the treatment of patients with leptomeningeal metastases (LM) Presented positive ReSPECT-GBM Trial Data at the 2024 Congress of Neurological Surgeons Annual Conference Established Radiotherapeutic Manufacturing Partnership with SpectronRx to meet late-stage clinical and commercial forecasts for Rhenium (186Re) Obisbemeda AUSTIN, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced financial results for the third quarter ended September 30, 2024, and provided an overview of recent and upcoming business...

Continue reading

Scorpius Holdings Reports Third Quarter 2024 Results, Highlighting Strategic Partnerships, Cost Savings, and Progress Toward Profitability

DURHAM, N.C., Nov. 14, 2024 (GLOBE NEWSWIRE) — Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today provided a strategic, financial, and operational update for the third quarter ended September 30, 2024. Jeff Wolf, CEO of Scorpius Holdings, Inc., stated, “Scorpius continued to make strides in Q3, driven by key partnerships, disciplined financial management, and growth across our manufacturing and development services. We are proud to report a 142% year-over-year increase in revenue for the nine months ended September 30, 2024, reaching $5.2 million, which illustrates the demand for our services and the successful expansion of our client base. Alongside this revenue growth, we achieved a 23.5% reduction in operating expenses...

Continue reading

Fluent Announces Third Quarter 2024 Financial Results; Strategic Pivot Accelerates with Growth of Commerce Media Solutions

Revenue of $64.5 million for Q3 2024 and $189.2 million for YTD 2024Commerce Media Solutions revenue grew 341% to $10.4 million (16% of revenue) from $2.3 (3% of revenue) in Q3 last year with gross profit margin of 33% in the quarter compared to 24% for the consolidated businessCommerce Media Solutions annual recurring run rate currently exceeds $50 million demonstrating strong traction in executing strategic pivot to a fast-growing marketNEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) — Fluent, Inc. (NASDAQ: FLNT), a partner monetization and customer acquisition solutions leader, today reported financial results for the third quarter and nine months ended September 30, 2024. Don Patrick, Fluent’s Chief Executive Officer, commented, “During the third quarter we continued to accelerate our shift in focus and revenue mix...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.